Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide Vaccination with Azacitidine in MDS and AML
NCT02750995Phase 1Completed
- Start
- Apr 2016
- Primary completion
- Jan 2018
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NPMW-peptide vaccine in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 24 months. Started Apr 2016; status: completed.
02
Drugs
NPMW-peptide vaccine
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02750995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750995.